Critical Review: Dipexium Pharmaceuticals (PLXP) and Kindred Biosciences (KIN)
Dipexium Pharmaceuticals (NASDAQ: PLXP) and Kindred Biosciences (NASDAQ:KIN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.
Volatility & Risk
Dipexium Pharmaceuticals has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Comparatively, Kindred Biosciences has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500.
Valuation & Earnings
This table compares Dipexium Pharmaceuticals and Kindred Biosciences’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Dipexium Pharmaceuticals||$375,950.00||157.14||-$8.09 million||N/A||N/A|
|Kindred Biosciences||N/A||N/A||-$24.99 million||($1.17)||-6.28|
Dipexium Pharmaceuticals has higher revenue and earnings than Kindred Biosciences.
This is a summary of recent recommendations and price targets for Dipexium Pharmaceuticals and Kindred Biosciences, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Kindred Biosciences has a consensus price target of $9.00, indicating a potential upside of 22.45%. Given Kindred Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Kindred Biosciences is more favorable than Dipexium Pharmaceuticals.
This table compares Dipexium Pharmaceuticals and Kindred Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
19.7% of Dipexium Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.4% of Kindred Biosciences shares are owned by institutional investors. 47.7% of Dipexium Pharmaceuticals shares are owned by insiders. Comparatively, 19.1% of Kindred Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Kindred Biosciences beats Dipexium Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
Dipexium Pharmaceuticals Company Profile
PLx Pharma Inc., formerly Dipexium Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen. PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. The Company’s lead product Aspertec 325 mg is a liquid-fill aspirin capsule for prevention of cardiovascular disease. Through PLxGuard delivery system the Company creates a lipid-based formulation of ibuprofen, PL1200 Ibuprofen Capsules, 200 mg.
Kindred Biosciences Company Profile
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company’s other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
Receive News & Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.